Papers
Topics
Authors
Recent
Detailed Answer
Quick Answer
Concise responses based on abstracts only
Detailed Answer
Well-researched responses based on abstracts and relevant paper content.
Custom Instructions Pro
Preferences or requirements that you'd like Emergent Mind to consider when generating responses
Gemini 2.5 Flash
Gemini 2.5 Flash 48 tok/s
Gemini 2.5 Pro 48 tok/s Pro
GPT-5 Medium 26 tok/s Pro
GPT-5 High 19 tok/s Pro
GPT-4o 107 tok/s Pro
Kimi K2 205 tok/s Pro
GPT OSS 120B 473 tok/s Pro
Claude Sonnet 4 37 tok/s Pro
2000 character limit reached

Statistical Inference for Data-adaptive Doubly Robust Estimators with Survival Outcomes (1709.00401v3)

Published 1 Sep 2017 in stat.ML

Abstract: The consistency of doubly robust estimators relies on consistent estimation of at least one of two nuisance regression parameters. In moderate to large dimensions, the use of flexible data-adaptive regression estimators may aid in achieving this consistency. However, $n{1/2}$-consistency of doubly robust estimators is not guaranteed if one of the nuisance estimators is inconsistent. In this paper we present a doubly robust estimator for survival analysis with the novel property that it converges to a Gaussian variable at $n{1/2}$-rate for a large class of data-adaptive estimators of the nuisance parameters, under the only assumption that at least one of them is consistently estimated at a $n{1/4}$-rate. This result is achieved through adaptation of recent ideas in semiparametric inference, which amount to: (i) Gaussianizing (i.e., making asymptotically linear) a drift term that arises in the asymptotic analysis of the doubly robust estimator, and (ii) using cross-fitting to avoid entropy conditions on the nuisance estimators. We present the formula of the asymptotic variance of the estimator, which allows computation of doubly robust confidence intervals and p-values. We illustrate the finite-sample properties of the estimator in simulation studies, and demonstrate its use in a phase III clinical trial for estimating the effect of a novel therapy for the treatment of HER2 positive breast cancer.

Summary

We haven't generated a summary for this paper yet.

List To Do Tasks Checklist Streamline Icon: https://streamlinehq.com

Collections

Sign up for free to add this paper to one or more collections.

Lightbulb On Streamline Icon: https://streamlinehq.com

Continue Learning

We haven't generated follow-up questions for this paper yet.

Authors (1)